All In Biotech

Drug Trial Radar · NCT05586776

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,700

Planned (sponsor's estimate)

Start

Jan 17, 2023

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, Davis; University of California, San Francisco; University of Massachusetts, Amherst; Hoag Memorial Hospital Presbyterian
First posted
Oct 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.

Conditions

  • Surgical Site Infection

Interventions

  • 4% Chlorhexidine GluconateDrug

    Used for daily showering/bathing for 30 days after hospital discharge.

  • 2% MupirocinDrug

    Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.

  • Soap Without Antiseptic Properties (Placebo)Drug

    Used for daily showering/bathing for 30 days after hospital discharge.

  • Placebo Nasal OintmentDrug

    Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Post-Discharge Surgical Site InfectionTime frame: Within 30 Days of Hospital Discharge

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • University of California, Irvine Medical Center

    Orange, California · Recruiting

  • University of California, Davis Medical Center

    Sacramento, California · Recruiting

  • University of California, San Francisco Medical Center

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.